Get the Stockscreener App
1.79
3.47%
0.06
Pre-market:
1.79
Coherus Oncology Inc stock is traded at $1.79, with a volume of 874.53K.
It is up +3.47% in the last 24 hours and up +3.47% over the past month.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
See More
Previous Close:
$1.73
Open:
$1.74
24h Volume:
874.53K
Relative Volume:
0.61
Market Cap:
$268.30M
Revenue:
$42.17M
Net Income/Loss:
$-183.12M
P/E Ratio:
-1.2292
EPS:
-1.4562
Net Cash Flow:
$-138.51M
1W Performance:
+1.13%
1M Performance:
+3.47%
6M Performance:
+14.38%
1Y Performance:
+75.49%
1-Day Range:
$1.74
$1.80
1-Week Range:
$1.701
$1.83
52-Week Range:
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
Name
Coherus Oncology Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.79 | 268.30M | 42.17M | -183.12M | -138.51M | -1.4562 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-26 | Initiated | Oppenheimer | Outperform |
| Sep-04-25 | Upgrade | Maxim Group | Hold → Buy |
| Aug-16-24 | Downgrade | UBS | Buy → Neutral |
| Nov-17-23 | Initiated | Robert W. Baird | Outperform |
| Nov-08-23 | Downgrade | Maxim Group | Buy → Hold |
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Oncology Inc Stock (CHRS) Latest News
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance
Coherus Oncology (CHRS) to Release Q1 2026 Financial Results - GuruFocus
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026 - The Manila Times
Coherus sets May 11 after-close call for Q1 results, business update - Stock Titan
Coherus Oncology (NASDAQ:CHRS) Stock Price Crosses Above 200-Day Moving AverageHere's Why - MarketBeat
Hepatic Tumor Pipeline Grows as 75+ Pharma Companies Advance - openPR.com
Satterfield reports 6.93M shares in Coherus Oncology (NASDAQ: CHRS) ownership filing - Stock Titan
BlackRock reports 4.9% stake in Coherus Oncology (CHRS) - Stock Titan
Coherus Oncology announces proposed public offering of common stock - MSN
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat
CHRS Price Today: Coherus Oncology, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Coherus Oncology prices stock offering to raise $50.1M - MSN
Is Coherus (CHRS) stock losing upward momentum (Bullish Sentiment) 2026-04-20Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai
[ARS] Coherus Oncology, Inc. SEC Filing - Stock Titan
[DEF 14A] Coherus Oncology, Inc. Definitive Proxy Statement - Stock Titan
Coherus (CHRS) Stock Signal Based Trade (Bullish Momentum) 2026-04-16Professional Trade Ideas - Cổng thông tin điện tử Tỉnh Sơn La
Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Coherus Oncology (CHRS) is one of the best penny stocks, here is why – corrected - MSN
Coherus Oncology Inc (STU:8C5) Stock Price & 30 Year Financial Data - GuruFocus
Certain Warrants of Coherus Oncology, Inc. are subject to a Lock-Up Agreement Ending on 14-APR-2026. - marketscreener.com
Certain Stock Options of Coherus Oncology, Inc. are subject to a Lock-Up Agreement Ending on 14-APR-2026. - marketscreener.com
Certain Common Stock of Coherus Oncology, Inc. are subject to a Lock-Up Agreement Ending on 14-APR-2026. - marketscreener.com
CHRS SEC FilingsCoherus 10-K, 10-Q, 8-K Forms - Stock Titan
What should investors watch in Coherus (CHRS) Stock | Price at $1.66, Down 1.49%Trending Volume Leaders - Cổng thông tin điện tử tỉnh Lào Cai
Coherus Oncology (CHRS) Is One of the Best Penny Stocks, Here is Why – Corrected - Yahoo Finance
Coherus Oncology (CHRS) proposes option repricing and 7.7M-share increase - Stock Titan
Coherus Oncology Receives 'Hold' Rating from Analysts - National Today
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Why The Coherus Oncology (CHRS) Story Is Shifting Around Growth Assumptions And Execution Risk - Yahoo Finance
Coherus Oncology (CHRS) upgraded to buy: Here's what you should know - msn.com
Vanguard disaggregates holdings; 0% stake in Coherus (NASDAQ: CHRS) - Stock Titan
If You Invested $1,000 in Coherus (CHRS) - Stock Titan
Metastatic Hepatocellular Carcinoma Clinical Trial Pipeline - openpr.com
Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Coherus Oncology (NASDAQ:CHRS) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
CHRS Technical Analysis & Stock Price Forecast - Intellectia AI
Coherus BioSciences Q4 2025 earnings preview - MSN
Coherus Oncology (CHRS) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf. - MarketBeat
Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen - MarketBeat
Coherus Oncology, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Coherus Oncology Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):